Leigh Syndrome Treatment Market Research Report -Forecast till 2027

Leigh Syndrome Treatment Market Research Report: By Diagnosis (MRI, CT, and Laboratory Test), By Treatment (Medications, Medical Procedure, and Surgery), By End User (Hospital, Research Organizations and Academic Institutes)- Forecast till 2027

ID: MRFR/HC/3811-HCR | | Region: Global | 90 pages

Leigh Syndrome Treatment Market Scenario


Leigh syndrome is a rare genetic disorder characterized by progressive damage to the central nervous system. This condition is caused due to defective functioning of mitochondria within the cells of the body. The symptoms are seen after birth which includes loss of head control and seizures. Various forms of leigh's disease have a poor prognosis. Most cases are fatal during childhood, although some individuals have reported surviving to adolescence. This progressive disorder begins in infants between the ages of three months to two years.


Leigh's disease can be caused by mutations in mitochondrial DNA or by deficiencies of an enzyme called pyruvate dehydrogenase. The risk of passing the abnormal gene from affected parent to offspring is 50 percent for each pregnancy. According to the United Mitochondrial Disease Foundation, the estimated incidence of Leigh’s disease is one in 77,000 births or one per 40,000 births for Leigh and Leigh-like disease. However, this may be an underestimate since mitochondrial diseases tend to be misdiagnosed. The disorders are due to a broad range of genetic mutations in both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA).


The most common treatment for Leigh's disease is thiamine or Vitamin B1. Oral sodium bicarbonate or sodium citrate may also be prescribed to manage lactic acidosis. Currently, dichloroacetate is being tested to establish its effectiveness in treating lactic acidosis. Leigh disease occurs in at least 1 of 40,000 live births, though certain populations have much higher rates.


The Global Leigh Syndrome Treatment Market is expected to grow at a CAGR of approximately 6.5% during the forecast period 2017-2023.


 


Research Methodology Leigh Syndrome Treatment Market


Sources: Annual reports, Press release, White paper, and Company presentation


Leigh Syndrome Treatment Market Key Players


The existing players are strengthening their foothold in the industry by introducing technologically advanced products. Some of key the players in the global leigh syndrome treatment market are GlaxoSmithKline Plc (GSK), Brother Enterprises (China), Huazhong Pharma (China), Zhejiang Tianxin (China),  Stryker Corporation (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), Wright Medical Technology, Inc. (U.S.), Integra LifeSciences Holdings Corporation (U.S.), and others.


Leigh Syndrome Treatment Market Segmentation


The leigh syndrome treatment is segmented on the basis of diagnosis, treatment, and end-users.


On the basis of the diagnosis, the leigh syndrome treatment market is segmented into magnetic resonance imaging (MRI), computed tomography (CT), laboratory test, and others. The laboratory test is divided into blood test, serum test, urine test, and others.


On the basis of the treatment, the market is segmented into medications, medical procedures, and surgery.


On the basis of the end-user, the market is segmented into the hospital, research organizations, and academic institutes.


Leigh Syndrome Treatment Market Regional Analysis


The global leigh syndrome treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.


The Americas is projected to hold the largest share of the global leigh syndrome treatment market due to the increasing mitochondrial disorders in the U.S. According to the National Center for Advancing Translational Science (NIH), Leigh syndrome is much more common in certain populations. For instance, the condition occurs in approximately 1 in 2,000 newborns in Quebec, Canada and approximately 1 in 1,700 in countries such as Norway and Iceland.


Europe is expected to capture the second lead in leigh syndrome treatment market in the coming five years owing to substantial technological advancements. The leigh syndrome treatment market in the Asia Pacific is expected to witness the fastest growth rate within the forecast period due to increasing birth rates coupled with increasing number of genetic disorders. The developing countries are facing a poor prognosis, with death usually occurring in childhood. The later the onset, the slower the deterioration. Death is most frequently due to respiratory failure. The Middle East and Africa leigh syndrome treatment market are also expected to show a healthy growth in the coming five years.


Intended Audience



  • Leigh Syndrome Devices Suppliers

  • Leigh Syndrome Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


 



TABLE OF CONTENT


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Leigh syndrome Treatment Market, by Diagnosis

6.1 Introduction

6.2 Magnetic resonance imaging (MRI)

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Computed tomography (CT)

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Laboratory test

6.4.1 Market Estimates & Forecast, 2020-2027

6.4.2 Blood test

6.4.2.1 Market Estimates & Forecast, 2020-2027

6.4.3 Serum test

6.4.3.1 Market Estimates & Forecast, 2020-2027

6.4.4 Urine test

6.4.4.1 Market Estimates & Forecast, 2020-2027

6.4.5 Others

6.5 Others

Chapter 7. Global Leigh syndrome Treatment Market, by Treatment

7.1 Introduction

7.2 Medications

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Medical Procedure

7.3.1 Market Estimates & Forecast, 2020-2027

7.4 Surgery

7.4.1 Market Estimates & Forecast, 2020-2027

Chapter 8. Global Leigh syndrome Treatment Market, by End User

8.1 Introduction

8.2 Hospital

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Research organizations

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Academic institutes

8.4.1 Market Estimates & Forecast, 2020-2027

Chapter. 9 Global Leigh syndrome Treatment Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 GlaxoSmithKline Plc

11.1.1 Company Overview

11.1.2 Treatment Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Brother Enterprises

11.2.1 Company Overview

11.2.2 Treatment Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Huazhong Pharma

11.3.1 Company Overview

11.3.2 Treatment Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Zhejiang Tianxin

11.4.1 Company Overview

11.4.2 Treatment/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Stryker Corporation.

11.5.1 Company Overview

11.5.2 Treatment Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Zimmer Biomet Holdings, Inc.

11.6.1 Company Overview

11.6.2 Treatment Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Wright Medical Technology

11.7.1 Overview

11.7.2 Treatment Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Integra LifeSciences Holdings Corporation

11.8.1 Company Overview

11.8.2 Treatment/Business Segment Overview

11.8.3 Financial Overview

11.8.4 Key Development

11.8.5 SWOT Analysis

11.9 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Bunion treatment Industry Synopsis, 2020-2027

Table 2 Leigh syndrome Treatment Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Leigh syndrome Treatment Market by Region, 2020-2027, (USD Million)

Table 4 Leigh syndrome Treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 5 Leigh syndrome Treatment Market by Treatment, 2020-2027, (USD Million)

Table 6 Leigh syndrome Treatment Market by End Users, 2020-2027, (USD Million)

Table 7 North America Leigh syndrome Treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 8 North America Leigh syndrome Treatment Market by Treatment, 2020-2027, (USD Million)

Table 9 North America Leigh syndrome Treatment Market by End User, 2020-2027, (USD Million)

Table 10 US Leigh syndrome Treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 11 US Leigh syndrome Treatment Market by Treatment, 2020-2027, (USD Million)

Table 12 US Leigh syndrome Treatment Market by End User, 2020-2027, (USD Million)

Table 13 Canada Leigh syndrome Treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 14 Canada Leigh syndrome Treatment Market by Treatment, 2020-2027, (USD Million)

Table 15 Canada Leigh syndrome Treatment Market by End User, 2020-2027, (USD Million)

Table 16 South America Leigh syndrome Treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 17 South America Leigh syndrome Treatment Market by Treatment, 2020-2027, (USD Million)

Table 18 South America Leigh syndrome Treatment Market by End User, 2020-2027, (USD Million)

Table 19 Europe Leigh syndrome Treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 20 Europe Leigh syndrome Treatment Market by Treatment, 2020-2027, (USD Million)

Table 21 Europe Leigh syndrome Treatment Market by End User, 2020-2027, (USD Million)

Table 22 Western Europe Leigh syndrome Treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 23 Western Europe Leigh syndrome Treatment Market by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe Leigh syndrome Treatment Market by End User, 2020-2027, (USD Million)

Table 25 Eastern Europe Leigh syndrome Treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 26 Eastern Europe Leigh syndrome Treatment Market by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe Leigh syndrome Treatment Market by End User, 2020-2027, (USD Million)

Table 28 Asia Pacific Leigh syndrome Treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 29 Asia Pacific Leigh syndrome Treatment Market by Treatment, 2020-2027, (USD Million)

Table 30 Asia Pacific Leigh syndrome Treatment Market by End User, 2020-2027, (USD Million)

Table 31 The Middle East & Africa Leigh syndrome Treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 32 The Middle East & Africa Leigh syndrome Treatment Market by Treatment, 2020-2027, (USD Million)

Table 33 The Middle East & Africa Leigh syndrome Treatment Market by End User, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Leigh syndrome Treatment Market

Figure 3 Segmentation Market Dynamics for Leigh syndrome Treatment Market

Figure 4 Global Leigh syndrome Treatment Market Share, by Diagnosis 2020

Figure 5 Global Leigh syndrome Treatment Market Share, by Treatment 2020

Figure 6 Global Leigh syndrome Treatment Market Share, by End Users, 2020

Figure 7 Global Leigh syndrome Treatment Market Share, by Region, 2020

Figure 8 North America Leigh syndrome Treatment Market Share, by Country, 2020

Figure 9 Europe Leigh syndrome Treatment Market Share, by Country, 2020

Figure 10 Asia Pacific Leigh syndrome Treatment Market Share, by Country, 2020

Figure 11 The Middle East & Africa Leigh syndrome Treatment Market Share, by Country, 2020

Figure 12 Global Leigh syndrome Treatment Market: Company Share Analysis, 2020 (%)

Figure 13 GlaxoSmithKline Plc: Key Financials

Figure 14 GlaxoSmithKline Plc: Segmental Revenue

Figure 15 GlaxoSmithKline Plc: Geographical Revenue

Figure 16 Brother Enterprises: Key Financials

Figure 17 Brother Enterprises: Segmental Revenue

Figure 18 Brother Enterprises: Geographical Revenue

Figure 19 Huazhong Pharma: Key Financials

Figure 20 Huazhong Pharma: Segmental Revenue

Figure 21 Huazhong Pharma: Geographical Revenue

Figure 22 Zhejiang Tianxin: Key Financials

Figure 23 Zhejiang Tianxin: Segmental Revenue

Figure 24 Zhejiang Tianxin: Geographical Revenue

Figure 25 Stryker Corporation: Key Financials

Figure 26 Stryker Corporation: Segmental Revenue

Figure 27 Stryker Corporation: Geographical Revenue

Figure 28 Zimmer Biomet Holdings, Inc..: Key Financials

Figure 29 Zimmer Biomet Holdings, Inc..: Segmental Revenue

Figure 30 Zimmer Biomet Holdings, Inc..: Geographical Revenue

Figure 31 Wright Medical Technology, Inc.: Key Financials

Figure 32 Wright Medical Technology, Inc.: Segmental Revenue

Figure 33 Wright Medical Technology, Inc.: Geographical Revenue

Figure 34 Integra LifeSciences Holdings Corporation: Key Financials

Figure 35 Integra LifeSciences Holdings Corporation: Segmental Revenue

Figure 36 Integra LifeSciences Holdings Corporation: Geographical Revenue



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.